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ABSTRACT 
Effective antiretroviral therapy remains beyond the reach of 
most human immunodeficiency virus (HIV-infected persons liv- 
ing in the third world because of its tremendous cost. The can- 
cer drug, hydroxyurea, inhibits HIV-l replication in vitro and, 
when combined with didanosine (ddl), results in significant anti- 
retroviral synergy. In vivo, hydroxyurea specifically targets qui- 
escent lymphocytes and macrophages, important cellular 
reservoirs for HIV-I, and the combination of ddl plus hydroxy- 
urea effectively reduces plasma HIV-l RNA levels. Combination 
ddl-hydroxyurea costs about one-eighth as much as currently 
recommended triple drug combinations, and several countries 
in Africa are exploring the feasibility of widescale use of ddl- 
hydroxyurea for their HIV-infected populations. Intrigued by its 
potential relevance for Africa, the authors reviewed the litera- 
ture on the in vitro and clinical efficacy of ddl plus hydroxyurea 
against HIV. The combination of ddl plus hydroxyurea is an 
effective and potentially more affordable regimen for HIV- 
infected persons living in poorer countries. 
Int J Infect Dis 2001; 5:43-48. 
In the past few years tremendous developments in the 
realm of combination antiviral therapy for human 
immunodeficiency virus (HIV) infection have offered 
hope for many persons afflicted with this deadly virus. 
Triple combination antiretroviral therapy consisting of 
two nucleoside analogue agents and a protease inhibitor 
can consistently reduce serum HIV-l RNA to unde- 
tectable levels, for periods up to 24 months, and with lit- 
tle or no development of drug resistance. l Unfortunately, 
the cost of such effective drug regimens (about U.S. 
$IO,OOO-12,OOO/yr) puts them out of reach for the vast 
majority of HIV-infected patients living in poorer coun- 
tries. In searching for more affordable treatment alter- 
natives, several African countries are examining the 
feasibility of making a combination of didanosine (dd1) 
and hydroxyurea more accessible to their citizens. In 
South Africa, for example, the cost of dd1 plus hydroxy- 
urea currently costs about 500 rand per month (about 
U.S. $100) compared with a zidovudine-lamivudine-indi- 
navir combination costing about 4000 rand per month 
(about U.S. $800). In this analysis, the authors review the 
substantial body of literature on the in vitro and clinical 
efficacy of dd1 plus hydroxyurea for HIV infection. 
MATERIALS AND METHODS 
Through a MEDLINE search and perusal of Index 
Medicus, a review was conducted of the relevant litera- 
ture for the period January 1993 through February 1998, 
to identify in vitro and clinical experiences with the com- 
bination of dd1 plus hydroxyurea for feline herpesvirus 
(FHV) infection. Eleven clinical studies were located and 
reviewed, and patient and treatment characteristics and 
virologic parameters were analyzed, including drug 
dosages, prior antiretroviral therapy and duration, pre- 
and post-treatment CD4 counts, effect on plasma HIV-l 
RNA levels (determined via quantitative polymerase chain 
reaction [PCR]), duration of antiviral efficacy, and adverse 
effects. 
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PHARMACOKINETIC AND IN VITRO STUDIES 
Pharmacoldnetically, hydroxyurea given orally to patients 
infected with HIV-l is well-absorbed from the gastro- 
intestinal tract and distributes widely throughout body 
fluids, including cerebrospinal fluid &SF), entering cells 
by passive diffusion. After oral administration of a 500-mg 
dose, the mean serum peak and trough concentrations are 
0.135 mmol/L and 0.0085 mmol/L, respectively, with a 
mean steady state concentration of 0.045 mrn01/L.~ Serum 
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levels of hydroxyurea range from 0.01 to 0.13 mmol& 
and are similar to the concentrations (between 0.01 and 
0.1 fnn~ol/L) demonstrated to inhibit HIV-l in macrophages 
in vitro.“z3 Fifty FM of hydroxyurea have a cytostatic but 
not cytolytic antiviral effect in vitro, and 100 FM of ddI am 
required to achieve a 95% inhibitory concentration (IC,,).* 
The in vitro activity of dd1 is significantly enhanced by the 
addition of hydroxyurea. 4-7 The IC,, for dd1 alone is 1.1 
(+- 0.11) @I, but with the addition of 50 uM of hydroxy- 
urea, the IC,, drops to 0.14 (2 0.05) PM.~ With the addi- 
tion of hydroxyurea, there is a 25- to lOO-fold reduction in 
the dose of dd1 required to achieve an IC,,.” 
CLINICAL STUDIES 
Table 1 details the patient demographics and clinical 
results from seven of the largest and longest clinical stud- 
ies reviewed.8-14 The dosage of orally administered 
hydroxyurea in six of these clinical studies was 500 mg 
twice daily; in one trial the dose was 250 mg four times 
daily. Didanosine was given as a 200 mg oral dose twice 
daily in all studies. A total of 147 persons, including 93 
antiretroviral treatment-naive patients received combined 
ddI-hydroxyurea therapy Pooled data revealed a signih- 
cant reduction in plasma HIV-l RNA levels (range, 1.0 
log,,, to 2.5) log,, decline; mean, 1.7 log,,, decline). In 13 
(54%) of 24 individuals tested at day 180 of therapy, 
plasma viral levels were undetectable (i.e., below of the 
threshold of 400 HIV-l RNA copies/mL).‘2 In persons 
receiving 1 year of treatment, ddI-hydroxyurea reduced 
plasma viral titers by a mean of 2.1 log,” in 10 (50%) of 
20 patientsI Viral reduction was sustained in all but one 
of the seven studies shown in Table 1, with up to 62 
weeks follow-up, and in two patients 1 year after dis- 
continuation of treatment.15 
In a dose-finding pilot study of hydroxyurea added to 
the treatment regimen of 26 patients with advanced HIV 
infection receiving chronic G 3 mo) dd1 therapy, median 
declines from baseline of 0.02 and 0.63 log,, HIV-l RNA 
copies/ml of plasma were observed for patients ran- 
domized to 500 mg/day and 1000 mg/day of hydroxy- 
urea, respectively (P = 0.02).’ During the 4-week 
treatment period, CD4+ cell counts did not increase sig- 
nificantly, although there was a small but statistically sig- 
nificant decrease in counts during the 1 month washout 
phase after hydroxyurea was discontinued. Similarly, a 
rebound in plasma virus load during the washout phase 
was also noted, supporting the in vivo antiviral efficacy 
of hydroxyurea. 
For six patients (three with acquired immunodefi- 
ciency syndrome [AIDS] and one with acute retroviral 
syndrome) treated with ddI-hydroxyurea, a rapid 
decrease in plasma HIV viremia (85% in all patients 
2-6 weeks after starting treatment) was observed and 
maintained in the absence of viral rebound for UP to 
62 weeks.’ In another trial involving 60 patients, these 
same authors compared dd1 monotherapy with dd1 plus 
hydroxyurea. ‘” An initial reduction in viral load of about 
1 .O log,,, was noted in both treatment groups; however, 
a rebound in serum HIV-l RNA levels began in the dd1 
monotherapy group at about week 4 and became sig- 
nificantly different from the combination group by week 
8. At 24 weeks, the mean viral load of the dd1 monother- 
apy group was only 52% below baseline, and viremia 
was back to baseline in 25% of the patients. For the 
20 patients in the ddI-hydroxyurea study arm, the initial 
decrease in viral load was sustained, and none of the 
18 patients who reached week 24 of follow-up showed 
any viral rebound. Seven consecutive patients were fur- 
ther treated with ddI-hydroxyurea, for almost 1 year; 
three of them had AIDS and three had received prior 
antiretroviral therapy. All patients, independent of clin- 
ical stage, responded to treatment with a mean drop in 
plasma viremia of about 1 .O log,,, and the drop was sus- 
tained for as long as 53 weeks. In a subsequent follow- 
up, these same investigators presented data on over 
40 patients who have received dd1 and hydroxyurea 
combination therapy for over 1 year with no evidence 
of breakthrough viral replication.16 
In a study by Biron and co-workers of 12 antiretro- 
viral-naive patients, combination treatment with dd1 and 
hydroxyurea reduced viral loads to undetectable levels 
in 7 (58%) of 12 patients as measured by infectious virus 
titer, and in 6 of 12 (50%) as measured by plasma HIV-l 
RNA.” Vila and colleagues reported that the combina- 
tion of ddl and hydroxyurea reduced and maintained HIV- 
1 viral loads to undetectable levels in plasma and lymph 
nodes of six of eight patients for up to 12 monthsI The 
concentration of HIV-l RNA in the lymph node mono- 
nuclear cell supernatant of five of seven of these patients 
was concomitantly undetectable or just slightly above 
the threshold of detectability. Only one individual had 
both demonstrable viremia and detectable infectious viri- 
ons in lymphoid tissue. These authors also described two 
patients who had no detectable infectious virus nor viral 
RNA in their plasma or lymphoid tissue after 1 year of 
combined treatment, and in whom no rebound in viral 
load could be documented 1 year after discontinuation 
of ddI-hydroxyurea therapy.15 Low levels of proviral DNA 
were detectable in these two patients, but the provirus 
was incompetent for transcription activity and, therefore, 
for the release of infective virions. 
Foli and co-workers evaluated the in vitro and in vivo 
effects of hydroxyurea added to both dd1 and zidovudine 
(AZT).14 The IC,, of AZT was decreased 4.6-fold by the 
addition of hydroxyurea (P = 0.3) compared to a 7.8fold 
decrease in the IC,, when hydroxyurea was added to ddI 
(P < 0. 001). A follow-up clinical study with five arms 
compared AZT, dd1, or hydroxyurea alone with the com- 
binations AZT plus hydroxyurea and ddl plus hydroxy- 
urea. The six subjects in the ddI-hydroxyurea group 
demonstrated a 1.43 log,, decrease in viral load at 
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Table 1. Patient Demographics and Treatment Outcome Measures in Patients 

















et a/l3 et a/l4 
Patients studied (n) 26 6 40 1.2 24 20 17 6 
Antiretroviral-naive patients (n) 0 4 20 12 24 20 11 1 
Duration of previous antiviral 16 NS - 23 NS 
treatment (mo) 
Stage of HIV infection NS Acute infection, Asymptomatic Asymptomatic Asymptomatic Asymptomatic NS CDC stage 
asymptomatic, Al or A2 
Daily ddl dosage (mg) 400 
Daily hydroxyurea dosage (g) 0.5; 1 
Duration of ddl-hydroxyurea 4wk 
treatment 
Baseline viral load (mean HIV-I 12,882 
RNA copies/ml) 
Decline in viral load 
Median or mean log,0 0.02; 0.63* 
Range log,0 0.02-2.4 
Patients with undetectable - 
viral loads after treatment (n) 
Mean or median baseline CD4+ 239 
count (cells/mm3) 
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NS = not significant; - = not stated; *Mean decrease in plasma viremia for 500 mg and 1000 mg doses of hydroxyurea, respectively; ‘All patients had CD4t counts 
> 250 cells/mm3; * The median increase in CD4+ count in these six patients was 244 cells/mm3; §ln seven patients the decline in viral load was > 1.5 loglO. 
2 weeks, with a 1.1 log,, decrease noted at 24 weeks of 
treatment. The differences in declines of viral load 
between the ddI-hydroxyurea and AZT-hydroxyurea 
groups, and between ddI-hydroxyurea and dd1 alone were 
statistically significant (P = 0.0065 and P = 0.037, respec- 
tively). Two of six patients in the AZT-hydroxyurea group 
experienced bone marrow toxicity that required drug 
withdrawal. 
In contrast to the trials showing clinical efficacy of 
ddI-hydroxyurea, in a small pilot study involving six 
patients receiving ddI-hydroxyurea for only 17 days 
Williams and co-workers could demonstrate a significant 
reduction in viral load in only three patients.” Their 
patients had more advanced immunosuppression than 
persons in other studies (the mean CD4+ count was 79 
cell/mm’), and only one of six patients was antiretroviral 
therapy-naive, although five were ddI-naive. Lafeuillade et 
al found no change in viremia in two patients with AIDS 
on dd1 therapy for less than 4 months in whom hydroxy- 
urea was added.‘* A third patient with AIDS-related com- 
plex, also receiving dd1, had a fivefold decrease in HIV 
viremia at week 4 compared with baseline. 
The combination of dd1 plus hydroxyurea appears 
unable to prevent the emergence of mutations that con- 
fer dd1 resistance, yet the mutants remain sensitive to 
standard doses of dd1 in the presence of hydroxyurea. 
Interestingly, although ddI-hydroxyurea may be associ- 
ated with the development of more codon mutations 
than dd1 monotherapy alone, Lori and co-workers have 
proposed that in vivo hydroxyurea lowers the levels of 
the cellular competitor of dd1, dATP, which allows for the 
incorporation of ddATP, the active metabolite of dd1, into 
the reverse transcription complex even if the reverse 
transcriptase is resistant to the nucleoside analogue.‘6 
No serious toxicities were noted in any of the clini- 
cal studies reviewed, and only one patient interrupted or 
discontinued ddI-hydroxyurea therapy because of adverse 
effects (gastrointestinal intolerance at week 9 of treat- 
ment). Minor gastrointestinal symptoms (nausea, diarrhea, 
vomiting) were noted occasionally. All of the patients in 
two studies (n = 36) developed an increase in mean cor- 
puscular volume (in one study from 88 to 102 fl), and 
four patients receiving combination therapy for more than 
360 days developed leukopenia (grade I, 3 patients; grade 
II, 1 patient). Grade II to III alopecia was observed in three 
persons with CD4+ counts less than 50 cells/mm”. Other 
rarely reported symptoms included headache (n = 4 
patients), dysuria (n = 3), stomatitis (n = 2), and palmar 
hyperpigmentation, paresthesias, and minor ulcerations of 
the mouth (n = 1 patient each). As an antimetabolite, 
hydroxyurea has potential teratogenic and carcinogenic 
effects, as has been noted previously in the oncologic lit- 
erature; its use in pregnant women is to be avoided.‘O 
DISCUSSION 
Although clinical studies demonstrate no antiretroviral 
activity of hydroxyurea by itself, with no decline in HIV 
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viral load and no increase in CD4+ cell cotmt,14,2s hydroxy- 
urea and dd1 provide a powerful drug combination that 
results in synergistic HIV-l inhibition.4-7x20.21 The anti- 
tetrovital activity of this drug combination appears to relate 
to (1) the increased phosphorylation of dd1 into the active 
metabolite, ddATP; (2) an inhibition of the cellular enzyme 
ribosomal ribonucleotide reductase, thus reducing the intra- 
cellular pool of deoxyribonucleotides and, in particular, 
dATP thereby allowing for more uptake of the ddATP 
metabolite into the viral genome with resulting enhanced 
viral inhibition; (3) the specific intracellular action of 
hydroxyurea within quiescent lymphocytes and macro- 
phage cell lines; (4) the action of dd1 in inhibiting the viral 
retrotranscription complex that may allow hydroxyurea 
to interact with HIV proteins such as ribonuclease H, lead- 
ing to the chelation of metalloproteins essential for viral 
replication; and (5) free radical scavenger activity of 
hydroxyurea, which may protect infected cells from lysis 
as a result of HIV-related oxidative damage.5-7x2”,21 
In the clinical studies included in this systematic 
review, the combination of dd1 plus hydroxyurea resulted 
in a marked viral load reduction of up to 2.9 log,,, and 
to undetectable levels in 39 (27%) of 147 patients treated. 
The decline in viral load is significantly greater in patients 
treated with the combination than in patients receiving 
dd1 alone, and is sustained during treatment for periods 
up to 62 weeks. The virologic benefit of combined dd1 
and hydroxyurea appears to be independent of disease 
stage or CD4+ cell count, although from the studies 
reviewed it appears that prior antiretroviral therapy with 
either AZT or dd1 may reduce the antiviral effect of the 
combination. The relatively modest increase in CD4+ cell 
counts observed in the studies reviewed here may be 
partly attributable to the cytostatic and myelosuppres- 
sive effects of hydroxyurea, which can lead to an overall 
decrease in total lymphocyte counts. 
Recently, the role of macrophages as a significant HIV 
source of viral load has been emphasized.23-2G The infec- 
tion of quiescent lymphocytes and macrophage cell lines 
contributes to the high viral load as disease progression 
occurs, and in episodes of intercurrent infection when acti- 
vation of these cells leads to an increase in viral DNA 
expression and viral RNA load.24-26 Hydroxyurea specih- 
tally targets macrophages and quiescent lymphocytes. As 
the therapeutic activity of some nucleoside analogues is 
diminished in HIV-infected macrophages and nonreplicat- 
ing lymphocytes, the accumulation of hydroxyurea in these 
quiescent cells affords a rationale for the synergy observed 
when it is combined with dd1. Further, the combination of 
ddI and hydroxyurea may be beneficial because it limits the 
number of activated T lymphocytes. 
Combining hydroxyurea with AZT has not shown 
the same consistent antiretroviral effect as ddI-hydroxy- 
urea, and the former combination is limited by enhanced 
bone marrow toxicity. Triple drug combinations consist- 
ing of hydroxyurea, dd1, and either stavudine (d4T) or a 
protease inhibitor are well-tolerated and may provide even 
more enhanced viral inhibition.27-31 Like ddI-hydroxyurea, 
these combinations also stabilize and improve CD4+ cell 
counts and viral load levels, and may help reconstitute the 
immune system by increasing the number of cells pro- 
grammed to protect against cellular injury and invasion. 
In analyzing the diversity of CD4+ cells in 42 treated 
patients followed for 7 months, Galpin et al demonstrated 
an immunorestorative potential for the combination of 
ddI-d4T-hydroxyurea. 29 They observed significant 
increases in various types of naive memory cells. At 20 
weeks, mean total naive lymphocytes (CD4RA) increased 
30% (P < 0.048) naive CD4-associated memory lympho- 
cytes (CD4CD45RA) increased 140% (P < 0.016) and 
CD45RA62L cells increased 222% (P < 0.054). Galpin and 
colleagues suggested that hydroxyurea-d4T-containing 
triple drug combinations may produce quiescent lym- 
phocytes and macrophages with suppressed HIV repli- 
cation and increased apoptosis of infected cells2” 
Admittedly, ddI-hydroxyurea provides only partial sup 
pression of HIV viral load; like zidovudine monotherapy, 
which was employed earlier in the HIV-AIDS epidemic, 
this partially-suppressive antiretroviral combination will 
undoubtedly lead to drug resistance and ultimate failure 
of the regimen, although even transient reductions in 
viral load will correlate with clinical benefit. Nevertheless, 
within the context of the critically limited treatment 
options available at the present time for HIV-infected 
patients in poor countries in Africa and elsewhere, the 
combination of dd1 plus hydroxyurea offers promise as 
a more affordable alternative to existing drug regimens. 
In many developing countries this regimen is likely to 
cost approximately one-third as much as the nearest- 
priced dual drug combination, and one-eighth as much as 
recommended triple drug combinations. In conclusion, 
in light of the accumulated clinical experience with the 
combination of dd1 plus hydroxyurea, efforts are under- 
way to expand the usage of this new treatment modality 
in South Africa. A prospective evaluation of 700 patients 
treated with ddI-hydroxyurea is underway. Improved 
health outcomes could provide a foundation for policy 
makers to promote and possibly finance this treatment 
strategy for certain subsets of patients with HIV infec- 
tion in this country 
ADDENDUM 
Since the acceptance of this article for publication, three 
additional research abstracts concerning the use of ddI- 
hydroxyurea-containing antiretroviral regimens were pre- 
sented at the World AIDS Conference in Geneva, June 
1998. 
In I2 of 40 patients previously randomized to receive 
ddI-hydroxyurea (median duration of treatment, 28 mo) 
plasma HIV-RNA decreased to undetectable levels in 11 
of 12 patients, although it took an unusually long time 
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(mean = 14 mo). (Seminari E, Maserati R, Lori F, Alberici 
F, Lisziewitz J. Long-term suppression of HIV with a sim- 
ple, nontoxic, inexpensive combination of didanosine 
plus hydroxyurea.) Federici and colleagues compared 
four antiretroviml regimens (ddI-hydroxyurea; ddI-hydroxy- 
urea-d4T; ddl-zidovudine; ddI-d4T, and found that plasma 
viral load fell 1.59 log,, and 1.76 log,, at 12 and 24 weeks, 
respectively, in the hydroxyurea groups (55, patients) com- 
pared with 1.59 log,, and 1.46 log,, for the non-hydroxy- 
urea groups (61 patients). The proportion of patients 
with undetectable viral loads (< 400 copies/ml of HIV- 
RNA) at weeks 12 and 24 were 58% and 6O%, respec- 
tively, in the hydroxyurea groups, and 58% and 43% in 
the non-hydroxyurea groups. (Federici ME, Lupo S, Cahn 
F’, et al. Hydroxyurea in combination regimens for the 
treatment of antiretroviral-naive HIV-infected adults.) 
In a nonrandomized, comparative trial of ddI-hydroxy- 
urea-d4T (17 patients) versus ddI-d4T-nelfinavir 
(9 patients) (median treatment duration, 45 mo), unde- 
tectable levels of HIV-RNA were achieved by week 4 in 
50% of patients in the hydroxyurea group, increasing to 
90% at week 12. Median viral load reduction was 1.2 log,,, 
for the hydroxyurea group compared with 1.7 log,,, for 
the non-hydroxyurea group. (Jaegel-Guacias E, Wolf E, 
Goeppner S, et al. d4T/ddl plus hydroxyurea: An alterna- 
tive to a PI-containing triple regimen in ART-naive HIV+ 
patients?) 
These three studies reached the same conclusions as 
our review article, namely, that the combination of dd1 
and hydroxyurea, is a safe, effective, and economically 
relevant alternative to existing antiretroviral regimens for 
poor patient populations. 
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